Corporate Profile

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection.